Zobrazeno 1 - 10 of 200 pro vyhledávání: '"Bernard, MJ."'
1
Akademický článek
Depression, Sleep Health & Sociodemographic Correlates in a Nationwide Survey: Implications for Depression Treatment During the COVID-19
Autor: Chery MJ, Baral A, Rolle LD, Abdshah A, Bernard MJ, Poudel L, Francois L, Jones DL, Jean-Louis G, Blanc J
Publikováno v: Nature and Science of Sleep, Vol Volume 16, Pp 17-31 (2024)
Maurice Junior Chery,1 Amrit Baral,1 LaShae D Rolle,1 Alireza Abdshah,1 Maritza J Bernard,2 Laxmi Poudel,3 Laura Francois,1 Deborah L Jones,4 Girardin Jean-Louis,4 Judite Blanc4 1Department of Public Health Sciences, the University of Miami Miller Sc
Externí odkaz: https://doaj.org/article/d8a524f982f04754b3a45038b61bce29
Zobrazit plný text záznamu
5
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
Autor: Zoë YGJ van Lierop, Samantha Noteboom, Martijn D Steenwijk, Maureen van Dam, Alyssa A Toorop, Zoé LE van Kempen, Bastiaan Moraal, Frederik Barkhof, Bernard MJ Uitdehaag, Menno M Schoonheim, Charlotte E Teunissen, Joep Killestein
Publikováno v: Multiple Sclerosis Journal, 28(14), 2231-2242. SAGE Publications Ltd
van Lierop, Z Y GJ, Noteboom, S, Steenwijk, M D, van Dam, M, Toorop, A A, van Kempen, Z L E, Moraal, B, Barkhof, F, Uitdehaag, B M J, Schoonheim, M M, Teunissen, C E & Killestein, J 2022, ' Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis ', Multiple Sclerosis Journal, vol. 28, no. 14, pp. 2231-2242 . https://doi.org/10.1177/13524585221118676
Background: Despite highly effective treatment strategies for patients with relapsing-remitting multiple sclerosis (RRMS), long-term neurodegeneration and disease progression are often considerable. Accurate blood-based biomarkers that predict long-t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4fb71ef2aefb5779c059be4ffa4d20
https://doi.org/10.1177/13524585221118676
Zobrazit plný text záznamu
6
Mapping the risk of infections in patients with multiple sclerosis
Autor: Leung, Melissa Wy, Bazelier, Marloes T, Souverein, Patrick C, Uitdehaag, Bernard Mj, Klungel, Olaf H, Leufkens, Hubert Gm, Pajouheshnia, Romin, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v: Leung, M W Y, Bazelier, M T, Souverein, P C, Uitdehaag, B M J, Klungel, O H, Leufkens, H G M & Pajouheshnia, R 2022, ' Mapping the risk of infections in patients with multiple sclerosis : A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum ', Multiple Sclerosis Journal, vol. 28, no. 11, pp. 1808-1818 . https://doi.org/10.1177/13524585221094218
Multiple Sclerosis Journal, 28(11), 1808-1818. SAGE Publications Ltd
Multiple sclerosis (Houndmills, Basingstoke, England), 28(11), 1808. SAGE Publications Ltd
Background: People with multiple sclerosis (pwMS) have an increased risk of infections; risk factors include underlying disease, physical impairment and use of some disease-modifying treatments. Objective: To quantify changes in population-level infe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42e7f4fa08bee00ee9014a0f056666d5
https://doi.org/10.1177/13524585221094218
Zobrazit plný text záznamu
7
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials
Autor: Eva MM Strijbis, Pavle Repovic, Jop Mostert, James D Bowen, Bernard MJ Uitdehaag, Gary Cutter, Marcus W Koch
Publikováno v: Multiple Sclerosis Journal, 28(10), 1606-1619. SAGE Publications Ltd
Strijbis, E M M, Repovic, P, Mostert, J, Bowen, J D, Uitdehaag, B M J, Cutter, G & Koch, M W 2022, ' The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials ', Multiple Sclerosis Journal, vol. 28, no. 10, pp. 1606-1619 . https://doi.org/10.1177/13524585221105465
Background: Patient-reported outcome measures (PROMs) are often used in clinical research, but little is known about their performance as longitudinal outcomes. Methods: We used data from ASCEND, a large SPMS trial ( n = 889), to investigate changes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f884d134aaccd214afc529979b8d6d5c
http://www.scopus.com/inward/record.url?scp=85134989329&partnerID=8YFLogxK
Zobrazit plný text záznamu
9
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations
Autor: Wallace J Brownlee, Christian Wolf, Hans-Peter Hartung, Theo Dingermann, Nadia Anshasi, Richard AC Clark, Maria Trojano, Krzysztof Selmaj, Bernard MJ Uitdehaag, Carmen Tur, Jens Wuerfel, Gabriele Dallmann, Julian Witte, Martina Sintzel, Olga Bobrovnikova, Jeffrey A Cohen
Publikováno v: Multiple Sclerosis Journal, 28(14), 2177-2189. SAGE Publications Ltd
Brownlee, W J, Wolf, C, Hartung, H-P, Dingermann, T, Anshasi, N, Clark, R A C, Trojano, M, Selmaj, K, Uitdehaag, B M J, Tur, C, Wuerfel, J, Dallmann, G, Witte, J, Sintzel, M, Bobrovnikova, O & Cohen, J A 2022, ' Use of follow-on disease-modifying treatments for multiple sclerosis : Consensus recommendations ', Multiple Sclerosis Journal, vol. 28, no. 14, pp. 2177-2189 . https://doi.org/10.1177/13524585221116269
Background: As patents for multiple sclerosis (MS) therapies expire, follow-on disease-modifying treatments (FO-DMTs) become available at reduced cost. Concerns exist that cheaper FO-DMTs are used simply to reduce healthcare costs. However, the well-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c5b38de7215defadd844af514b4860
https://doi.org/10.1177/13524585221116269
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje